2017 Revenue of $233.3 million, growth of 89%; 4Q 2017 Revenue of $77.1 million, growth of 106%
Total Paid Membership of 23.2 million, growth of 33%
2017 Visits of 1,463,000, growth of 54%; 4Q 2017 Visits of 464,000, growth of 49%
PURCHASE, NY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Teladoc, Inc. (NYSE:TDOC), the largest and most trusted provider of virtual care delivery services, today announced results for the full-year and fourth-quarter ended December 31, 2017.
“Teladoc demonstrated very strong performance in the fourth quarter, delivering results that were at or above our expectations on all key metrics. We made meaningful progress across all segments of our business, and take excellent momentum into 2018," said Jason Gorevic, chief executive officer, Teladoc. “Our unique product portfolio and value proposition is being recognized by clients and prospects alike for its breadth and differentiation, as virtual care becomes a core component of the healthcare system of the future.”
“In addition to our strong results, we were pleased to see favorable developments coming out of Washington, with supportive language in the Bipartisan Budget Act that paves the way for virtual care to serve every segment of the healthcare market, including the Medicare population.”
Financial Performance for the Fourth Quarter and Full-Year Ended December 31, 2017
All comparisons are to the fourth quarter and full-year ended December 31, 2016.
A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.
Business Outlook
First Quarter 2018 Guidance: Revenue for the first quarter 2018 is expected to be in the range of $86 million to $88 million. EBITDA is expected to be in the range of a loss of $12.0 million to a loss of $13.0 million. Adjusted EBITDA is expected to be in the range of a loss of $2.5 million to a loss of $3.5 million. Total U.S. paid membership is expected to total approximately 19.5 million to 20.0 million and visit fee only access are expected to total between of 9.0 million to 9.25 million individuals at March 31, 2018. Total visits are projected to be between 575,000 and 625,000. First quarter net loss per share, based on 61.9 million weighted average shares outstanding, is expected to be between $(0.43) and $(0.45).
Full Year 2018 Guidance: Revenue for 2018 is expected to be in the range of $350 million to $360 million. EBITDA is expected to be in the range of a loss of $27 million to $30 million. Adjusted EBITDA is expected to be positive in the range of $7 million to $10 million. Total U.S. paid membership is expected to be approximately 22 million to 24 million, plus visit fee only access should be available to approximately 19 million individuals. Total visits are projected to be between 1.9 million to 2.0 million visits. Net loss per share, based on 62.8 million weighted average shares outstanding, is expected to be between $(1.36) and $(1.41).
Quarterly Conference Call
The full year and fourth quarter 2017 earnings conference call and webcast will be held Tuesday, February 27, 2018 at 4:15 p.m. ET. The conference call can be accessed by dialing 1-833-241-4255 for U.S. participants, or 1-647-689-4206 for international participants, and including the following Conference ID Number: 6993917 to expedite caller registration; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.
About Teladoc, Inc.
Teladoc, Inc. (NYSE:TDOC) is the largest and most trusted telehealth provider in the world. Recognized by MIT Technology Review as one of the “50 Smartest Companies”, Teladoc is forging a new healthcare experience with better convenience, outcomes and value. The company provides virtual access to high quality care and expertise, with a portfolio of services and solutions covering 450 medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. By marrying the latest in data and analytics with its award-winning user experience and highly flexible technology platform, Teladoc has delivered millions of medical visits to patients around the globe. For additional information, please visit www.teladoc.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; and (v) changes to our abilities to recruit and retain qualified providers into our network. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) | ||||||||
As of December 31, | ||||||||
2017 | 2016 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 42,817 | $ | 50,015 | ||||
Short-term investments | 79,489 | 15,793 | ||||||
Accounts receivable, net of allowance of $2,422 and $2,422, respectively | 27,094 | 13,806 | ||||||
Prepaid expenses and other current assets | 6,839 | 3,103 | ||||||
Total current assets | 156,239 | 82,717 | ||||||
Property and equipment, net | 8,963 | 7,479 | ||||||
Goodwill | 498,520 | 188,184 | ||||||
Intangible assets, net | 159,811 | 24,875 | ||||||
Other assets | 858 | 415 | ||||||
Total assets | $ | 824,391 | $ | 303,670 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,884 | $ | 2,236 | ||||
Accrued expenses and other current liabilities | 19,357 | 7,981 | ||||||
Accrued compensation | 17,089 | 8,856 | ||||||
Other debt - current portion | — | 2,000 | ||||||
Total current liabilities | 40,330 | 21,073 | ||||||
Other liabilities | 4,882 | 7,609 | ||||||
Deferred taxes | 12,906 | 1,694 | ||||||
Long term bank and other debt, net | — | 42,424 | ||||||
Convertible senior notes, net | 207,370 | — | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Common stock, $0.001 par value; 100,000,000 shares and 75,000,000 shares authorized as of December 31, 2017 and 2016, respectively; 61,534,101 shares and 46,201,563 shares issued and outstanding as of December 31, 2017 and 2016, respectively | 61 | 46 | ||||||
Additional paid-in capital | 866,330 | 435,551 | ||||||
Accumulated deficit | (311,577 | ) | (204,726 | ) | ||||
Accumulated other comprehensive income (loss) | 4,089 | (1 | ) | |||||
Total stockholders’ equity | 558,903 | 230,870 | ||||||
Total liabilities and stockholders’ equity | $ | 824,391 | $ | 303,670 |
CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) | ||||||||||||||||
Unaudited | ||||||||||||||||
Quarters Ended December 31, | Year Ended December 31, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Revenue | $ | 77,140 | $ | 37,400 | $ | 233,279 | $ | 123,157 | ||||||||
Cost of revenue | 22,716 | 10,025 | 61,623 | 31,971 | ||||||||||||
Gross profit | 54,424 | 27,375 | 171,656 | 91,186 | ||||||||||||
Operating expenses: | ||||||||||||||||
Advertising and marketing | 18,441 | 9,820 | 57,663 | 34,720 | ||||||||||||
Sales | 11,279 | 7,451 | 37,984 | 26,243 | ||||||||||||
Technology and development | 10,446 | 5,894 | 34,459 | 21,815 | ||||||||||||
Legal | 760 | 769 | 1,485 | 4,117 | ||||||||||||
Regulatory | 616 | 721 | 3,387 | 3,158 | ||||||||||||
Acquisition and integration related costs | 2,557 | — | 13,196 | 6,959 | ||||||||||||
General and administrative | 27,482 | 13,353 | 79,781 | 48,568 | ||||||||||||
Depreciation and amortization | 7,402 | 2,597 | 19,095 | 8,270 | ||||||||||||
Loss from operations | (24,559 | ) | (13,230 | ) | (75,394 | ) | (62,664 | ) | ||||||||
Amortization of warrants and loss on extinguishment of debt | 12,665 | — | 14,122 | 8,454 | ||||||||||||
Interest expense, net | 7,813 | 881 | 17,491 | 2,588 | ||||||||||||
Net loss before taxes | (45,037 | ) | (14,111 | ) | (107,007 | ) | (73,706 | ) | ||||||||
Income tax (benefit) provision | (654 | ) | (150 | ) | (225 | ) | (510 | ) | ||||||||
Net loss | $ | (44,383 | ) | $ | (13,961 | ) | $ | (106,782 | ) | $ | (74,216 | ) | ||||
Net loss per share, basic and diluted | $ | (0.76 | ) | $ | (0.31 | ) | $ | (1.93 | ) | $ | (1.75 | ) | ||||
Weighted-average shares used to compute basic and diluted net loss per share | 58,371,458 | 46,081,831 | 55,427,460 | 42,330,908 | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | |||||||||
Year Ended December 31, | |||||||||
2017 | 2016 | ||||||||
Cash flows used in operating activities: | |||||||||
Net loss | $ | (106,782 | ) | $ | (74,216 | ) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | 19,095 | 8,270 | |||||||
Allowance for doubtful accounts | 1,731 | 2,412 | |||||||
Stock-based compensation | 30,597 | 7,723 | |||||||
Deferred income taxes | (306 | ) | 510 | ||||||
Accretion of interest | 6,382 | 262 | |||||||
Amortization of warrants and loss on extinguishment of debt | 14,122 | 7,717 | |||||||
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | (3,659 | ) | (2,900 | ) | |||||
Prepaid expenses and other current assets | (2,003 | ) | (826 | ) | |||||
Other assets | 98 | (42 | ) | ||||||
Accounts payable | 1,534 | (813 | ) | ||||||
Accrued expenses and other current liabilities | 4,292 | (2,301 | ) | ||||||
Accrued compensation | 3,768 | 1,688 | |||||||
Other liabilities | (3,310 | ) | 641 | ||||||
Net cash used in operating activities | (34,441 | ) | (51,875 | ) | |||||
Cash flows (used in) provided by investing activities: | |||||||||
Purchase of property and equipment | (2,633 | ) | (2,108 | ) | |||||
Purchase of internal-use software | (2,882 | ) | (1,304 | ) | |||||
Purchase of marketable securities | (149,261 | ) | (44,146 | ) | |||||
Proceeds from marketable securities | 85,753 | 110,717 | |||||||
Acquisition of business, net of cash acquired | (379,356 | ) | (37,013 | ) | |||||
Net cash (used in) provided by investing activities | (448,379 | ) | 26,146 | ||||||
Cash flows provided by financing activities: | |||||||||
Net proceeds from the exercise of stock options | 10,837 | 2,524 | |||||||
Proceeds from issuance of convertible notes | 263,722 | — | |||||||
Proceeds from borrowing under bank and other debt | 166,679 | 34,990 | |||||||
Repayment of bank borrowings and other debt | (226,440 | ) | (17,166 | ) | |||||
Proceeds from issuance of common stock | 258,554 | 250 | |||||||
Proceeds from employee stock purchase plan | 2,153 | — | |||||||
Cash for withholding taxes on stock-based awards, net | (74 | ) | 80 | ||||||
Net cash provided by financing activities | 475,431 | 20,678 | |||||||
Net (decrease) increase in cash and cash equivalents | (7,389 | ) | (5,051 | ) | |||||
Foreign exchange difference | 191 | — | |||||||
Cash and cash equivalents at beginning of the period | 50,015 | 55,066 | |||||||
Cash and cash equivalents at end of the period | $ | 42,817 | $ | 50,015 | |||||
Income taxes paid | $ | 137 | $ | — | |||||
Interest paid | $ | 9,450 | $ | 2,387 |
Non-GAAP Financial Measures:
To supplement our financial information prepared in accordance with GAAP, we use EBITDA and Adjusted EBITDA, which are non-GAAP financial measures, for business planning purposes and in measuring our performance relative to that of our competitors. EBITDA consists of net loss before interest, taxes, depreciation and amortization. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, amortization of warrants and loss on extinguishment of debt and acquisition and integration related costs. A reconciliation of these Non-GAAP financial measures is presented below to net loss, which we believe is the most directly comparable GAAP measure.
We believe that the presentation of these non-GAAP financial measures enhances an investor’s understanding of our financial performance and are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not comparable across reporting periods or that do not otherwise relate to the Company’s ongoing operating results
Our use of the term EBITDA and Adjusted EBITDA may vary from that of others in our industry. Neither EBITDA nor Adjusted EBITDA should be considered as an alternative to net loss or any other performance measures derived in accordance with GAAP as measures of performance.
EBITDA and Adjusted EBITDA have important limitation as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
EBITDA and Adjusted EBITDA:
We compensate for these limitations by using EBITDA and Adjusted EBITDA along with other comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of operating performance. Such U.S. GAAP measurements include gross profit, net loss, net loss per share and other performance measures.
In evaluating these financial measures, you should be aware that in the future we may incur expenses like those eliminated in this presentation. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
Reconciliation of EBITDA and Adjusted EBITDA to Net Loss (In thousands, unaudited) | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Net loss | $ | (44,383 | ) | $ | (14,261 | ) | $ | (106,782 | ) | $ | (74,216 | ) | ||||
Add: | ||||||||||||||||
Interest expense, net | 7,813 | 881 | 17,491 | 2,588 | ||||||||||||
Income tax (benefit) provision | (654 | ) | 150 | (225 | ) | 510 | ||||||||||
Depreciation expense | 1,305 | 634 | 3,771 | 2,176 | ||||||||||||
Amortization expense | 6,097 | 1,963 | 15,324 | 6,094 | ||||||||||||
EBITDA | (29,822 | ) | (10,633 | ) | (70,421 | ) | (62,848 | ) | ||||||||
Stock-based compensation | 16,969 | 2,636 | 30,597 | 7,723 | ||||||||||||
Amortization of warrants and loss on extinguishment of debt | 12,665 | — | 14,122 | 8,454 | ||||||||||||
Acquisition and integration related costs | 2,557 | — | 13,196 | 6,959 | ||||||||||||
Adjusted EBITDA | $ | 2,369 | $ | (7,997 | ) | $ | (12,506 | ) | $ | (39,712 | ) |
Media:
Courtney McLeod
914-265-6789
cmcleod@teladoc.com
Investors:
Westwicke Partners
Jordan E. Kohnstam
Office: 443-450-4189
Jordan.kohnstam@westwicke.com